Turn Therapeutics is a pharmaceutical and medical device company boasting 3 FDA Marketing Approvals, a licensing agreement with MiMedx ($70MM+ total expected value), and a track record of 200,000+ applications of its flagship formula, Hexagen®. The company seeks to expand the indications of this flagship formula to target moderate to severe eczema and onychomycosis (toenail fungus), both of which are underserved, multi-billion dollar markets. Global Health Solutions, Inc., d/b/a Turn Therapeutics, is currently pre-revenue, similar to other pharma development companies at this stage of development.